What Is Saxenda (Liraglutide)? Dosing, Weight Loss Data, Cost, and How It Compares

How Saxenda Works: GLP-1 Receptor Activation

Saxenda mimics GLP-1, an incretin hormone released from the gut after eating, to reduce hunger signals and slow how quickly food leaves the stomach. The result is earlier satiety and lower caloric intake without the subjective experience of willpower-driven dieting. Liraglutide binds to GLP-1 receptors in the hypothalamus and brainstem to modulate appetite circuitry [1].

The Incretin Effect and Appetite Regulation

Native GLP-1 has a half-life of roughly 2 minutes. Liraglutide's fatty-acid side chain allows it to bind albumin, extending its half-life to approximately 13 hours and making once-daily dosing possible [2]. This pharmacokinetic profile differs from semaglutide, whose half-life of roughly 168 hours supports weekly dosing.

Beyond Appetite: Metabolic Effects

GLP-1 receptor activation also enhances glucose-dependent insulin secretion and suppresses glucagon release. In the SCALE Diabetes trial (N=846), participants with type 2 diabetes on liraglutide 3.0 mg achieved a mean HbA1c reduction of 1.3 percentage points compared to 0.3 with placebo at 56 weeks [3]. These glycemic benefits are why liraglutide 1.8 mg (marketed as Victoza) was first approved for type 2 diabetes in 2010, years before the higher 3.0 mg dose gained its obesity indication [4].

Receptor Selectivity

Liraglutide is a selective GLP-1 receptor agonist. It does not activate GIP receptors (the target of tirzepatide's dual agonism) or glucagon receptors (targeted by retatrutide's triple agonism). This single-receptor profile partly explains its more moderate weight-loss efficacy relative to newer dual- and triple-agonist molecules.

Clinical Trial Evidence for Saxenda

The SCALE (Satiety and Clinical Adiposity, Liraglutide Evidence) program is the largest clinical trial program conducted for liraglutide 3.0 mg. It included four randomized, double-blind, placebo-controlled trials enrolling more than 5,300 participants across multiple countries [5].

SCALE Obesity and Prediabetes

The flagship SCALE trial randomized 3,731 adults without diabetes (BMI ≥30, or ≥27 with dyslipidemia or hypertension) to liraglutide 3.0 mg or placebo, both with lifestyle counseling. At 56 weeks, the liraglutide group lost a mean of 8.0% of body weight versus 2.6% for placebo. A total of 63.2% of participants on liraglutide achieved ≥5% weight loss, compared with 27.1% on placebo [5]. The 3-year extension showed that participants who continued liraglutide maintained greater weight loss and had a 66% reduction in the risk of developing type 2 diabetes compared to placebo [6].

SCALE Maintenance

This trial (N=422) enrolled adults who had already lost ≥5% of body weight through a low-calorie diet before randomization. Participants on liraglutide 3.0 mg lost an additional 6.2% of body weight over 56 weeks, while the placebo group regained 0.2% [7]. The Endocrine Society's 2024 Clinical Practice Guideline on Pharmacological Management of Obesity states: "Liraglutide 3.0 mg is recommended as an option for chronic weight management in adults who meet BMI criteria, with the understanding that newer GLP-1 receptor agonists may produce greater weight reduction" [8].

Adolescent Data

In the SCALE Teens trial (N=251), adolescents aged 12 to 17 with obesity received liraglutide 3.0 mg or placebo for 56 weeks. The liraglutide group achieved a mean BMI reduction of 4.64% versus a 3.14% increase with placebo, a treatment difference of 7.78 percentage points [9]. The FDA expanded Saxenda's label in December 2020 to include this population.

Dosing and Administration

Saxenda requires a 4-week dose escalation to minimize gastrointestinal side effects. Patients inject subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites daily.

Titration Schedule

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5 onward: 3.0 mg daily (maintenance)

If a patient cannot tolerate an increased dose, the FDA label permits delaying the escalation by an additional week at the current dose. Patients who cannot tolerate the 3.0 mg maintenance dose should discontinue [10].

The 16-Week Rule

The FDA label includes a stopping rule. If a patient has not lost at least 4% of baseline body weight by 16 weeks on the full 3.0 mg dose, Saxenda should be discontinued because sustained clinically meaningful weight loss is unlikely with continued treatment [10]. Dr. W. Timothy Garvey, chair of the department of nutrition sciences at the University of Alabama at Birmingham, has noted: "The 4% threshold at 16 weeks is a practical early signal. Patients who do not respond by that point rarely become late responders, and the cost-benefit calculus shifts against continuation" [8].

Storage and Handling

Unused Saxenda pens should be stored refrigerated at 2°C to 8°C (36°F to 46°F). After first use, a pen can be stored at room temperature (up to 30°C / 86°F) or refrigerated for up to 30 days. Each pen contains enough liraglutide for multiple doses, depending on the current titration step.

Side Effects and Safety Considerations

The most common adverse events with Saxenda are gastrointestinal. In the SCALE program, nausea occurred in 39.3% of liraglutide-treated patients versus 14.7% on placebo [5]. Most nausea was mild to moderate and peaked during dose escalation, declining substantially by weeks 8 to 12.

Gastrointestinal Effects

Diarrhea (20.9% vs. 9.9%), constipation (19.4% vs. 8.5%), and vomiting (15.7% vs. 4.1%) were the next most frequent GI complaints in the SCALE trials [5]. Slowing the titration schedule to 2-week intervals per step, rather than weekly, can reduce these effects in sensitive patients, though this approach is off-label.

Serious Warnings

Saxenda carries a boxed warning regarding thyroid C-cell tumors. Liraglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures. While this finding has not been confirmed in humans, Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [10]. Acute pancreatitis has been reported in post-marketing surveillance. The SCALE trials recorded pancreatitis at a rate of 0.3% with liraglutide versus 0.1% with placebo [5]. Patients should be counseled to report severe, persistent abdominal pain.

Heart Rate Increase

In pooled SCALE data, liraglutide 3.0 mg was associated with a mean resting heart rate increase of 2.0 beats per minute compared to placebo [11]. The LEADER cardiovascular outcomes trial (which studied liraglutide 1.8 mg in type 2 diabetes, N=9,340) demonstrated a 13% reduction in major adverse cardiovascular events (MACE) over 3.8 years, providing cardiovascular safety reassurance for the liraglutide molecule [12]. The higher 3.0 mg dose has not been studied in a dedicated cardiovascular outcomes trial for obesity.

How Saxenda Compares to Other GLP-1 Medications

Saxenda was the first GLP-1 receptor agonist approved specifically for weight management. Several newer options now exist, and understanding the differences helps patients and clinicians make informed choices.

Saxenda vs. Wegovy (Semaglutide 2.4 mg)

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg (Wegovy) produced a mean weight loss of 14.9% at 68 weeks compared with 2.4% for placebo [13]. This roughly doubles the efficacy seen with liraglutide 3.0 mg. Wegovy also requires only weekly injection versus Saxenda's daily dosing. The SELECT cardiovascular outcomes trial (N=17,604) showed semaglutide 2.4 mg reduced MACE by 20% in adults with obesity and established cardiovascular disease [14]. No equivalent dedicated trial exists for Saxenda at the 3.0 mg dose.

Saxenda vs. Zepbound (Tirzepatide)

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produced 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose versus 3.1% for placebo [15]. This represents the highest weight-loss efficacy among currently approved anti-obesity medications. Tirzepatide is administered weekly.

When Saxenda Still Makes Sense

Saxenda may be preferred for patients who want a lower-potency starting option, those who have responded well to liraglutide 1.8 mg (Victoza) for diabetes and want to intensify, or adolescents aged 12 to 17 (an indication Wegovy also holds, but clinical familiarity with Saxenda in teens is longer). Generic liraglutide for obesity is not yet available in the United States as of 2026, though Novo Nordisk's composition-of-matter patent expired in 2023, and device patents extend coverage further.

Cost, Insurance, and Access

Saxenda's list price in the United States is approximately $1,349 for a 30-day supply (five 3 mL pens at the 3.0 mg maintenance dose) [16]. Out-of-pocket costs vary widely depending on insurance formulary placement.

Insurance Coverage Field

Many commercial insurers now cover at least one GLP-1 receptor agonist for weight management, though Saxenda is increasingly placed on higher tiers or subject to step therapy requiring a trial of Wegovy first. Medicare Part D generally does not cover anti-obesity medications, though the Treat and Reduce Obesity Act, if enacted, would change this [17].

Savings Programs

Novo Nordisk offers a patient savings card that can reduce costs to as low as $200 per month for commercially insured patients. Eligibility excludes government-funded insurance programs. For uninsured patients, Novo Nordisk's Patient Assistance Program (PAP) provides Saxenda at no cost to qualifying individuals with household incomes at or below 400% of the federal poverty level [16].

Compounded Liraglutide

Some compounding pharmacies have offered liraglutide at lower prices. The FDA has stated that compounded versions of GLP-1 receptor agonists carry risks related to sterility, potency, and quality control that do not apply to FDA-approved products [18]. Patients considering compounded alternatives should discuss the risk-benefit profile with their prescriber.

Starting Saxenda: What to Expect in the First 90 Days

The initial 90-day period on Saxenda follows a predictable pattern that helps set realistic expectations for both weight loss trajectory and side-effect management.

Weeks 1 Through 4: Titration Phase

Appetite suppression often becomes noticeable at the 1.2 mg or 1.8 mg dose. Weight loss during titration averages 1 to 2 kg, though individual variation is significant. Nausea is most pronounced during this period. Eating smaller meals, avoiding high-fat foods, and staying hydrated are the standard mitigation strategies outlined in the prescribing information [10].

Weeks 5 Through 12: Early Maintenance

Once at 3.0 mg, most patients experience steady weight loss of approximately 0.5 to 1.0 kg per week. GI side effects typically plateau and begin to improve. Clinicians should check in at week 8 to assess tolerability and reinforce dietary and exercise counseling.

Week 16: The Decision Point

The 4% weight-loss threshold applies here. Patients meeting this benchmark can expect continued gradual weight loss through week 56 and beyond. Those who have not met the threshold should transition to an alternative agent or approach. Blood pressure, fasting glucose, and lipid panels are reasonable lab checks at the 16-week mark to document metabolic improvements that may support continued insurance authorization.

Discontinuation and Weight Regain

Weight regain after stopping Saxenda is common and well-documented. In the 3-year SCALE extension, participants who switched from liraglutide to placebo at week 160 regained approximately two-thirds of the weight they had lost within 12 weeks [6]. This pattern is consistent across all anti-obesity medications studied to date and reflects the chronic, relapsing nature of obesity as a disease.

Managing the Transition Off Saxenda

There is no required taper. Patients can stop Saxenda abruptly without withdrawal symptoms. The clinical challenge is behavioral: appetite returns to pre-treatment levels within days to weeks. Structured meal planning, increased physical activity, and in some cases transition to another medication (such as semaglutide or tirzepatide) are common strategies to mitigate regain.

The 2024 American Association of Clinical Endocrinology (AACE) consensus statement recommends that clinicians "plan for long-term pharmacotherapy from the outset, as discontinuation of anti-obesity medications predictably leads to weight regain in the majority of patients" [19].